Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Increased expression of Fz5 receptor matched with a decrease in NeuN immunoreactivity at 16w. by Carlos González-Fernández (2794207)

(A) Decreasing CaMKII activity by KN-93 (high-3 µmol/L, low-0.5 µmol/L), AIP (high-10 µmol/L, low-2 µmol/L), or decreasing calmodulin activity by W-7 (high-50 µmol/L, low-20 µmol/L) decreases spontaneous AP firing rate (n = 10 for each drug), cAMP (n = 4 for each drug) and ATP (n = 5 for each drug). by Yael Yaniv (162548)

AAV-mediated Atp6v1c1 knockdown decreased TRAP positive cells and Atp6v1c1 expression in the periodontitis lesion area. by Sheng Li (107261)

Cooperativity decreases with the expression level of CheA. by Stephan Eismann (835052)

Exercise test characteristics for identifying stenosis ≥ 50% in any limb among the 60 limbs with normal ABIs (> 0.91). by O. Stivalet (6890189)

Average changes in (A) spontaneous AP firing rate, (B) ATP and (C) cAMP by decreasing CaMKII activity with KN-93 (high-3 µmol/L, low-0.5 µmol/L), AIP (high-10 µmol/L, low-2 µmol/L), or decreasing calmodulin activity by W-7 (high-50 µmol/L, low-20 µmol/L). by Yael Yaniv (162548)

The distributions of the end-simulation adolescence-limited proportion when (a) <i>k</i> is increased or decreased by 50%, (b) <i>c</i> is increased or decreased by 50%, (c) <i>γ</i> is increased or decreased by 50%, and (d) Δ<i>e</i> is increased or decreased by 50%, compared against the benchmark distribution <i>F</i>(<b>p</b>₀) for the parameters shown in Table 1. by Jia Ning Leaw (752775)

Test characteristics for identifying stenosis ≥ 50% in any limb from aorta till popliteal artery in the overall population (<i>n = 126 limbs</i>). by O. Stivalet (6890189)

MEK5 expression decreases ER signaling and confers endocrine resistance. by James W. Antoon (444010)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Affinity analysis results (with a confidence level above 50%). by Marta R. Jabłońska (8491404)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

EC50 and percentage decrease in intracellular <i>Listeria</i> viability for effective compounds. by Marie-Eve Charbonneau (5658799)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

LuxR G37V has decreased DNA-binding activity. by Chelsea A. Simpson (9579303)

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

EphA4 immunostaining is decreased adjacent to injury site in ephrin-A5-Fc treated mice. by Yona Goldshmit (205708)

“…Arrows indicate lesion site. Scale bars in A–D, G,H, 100 µm; E,F, 50 µm.</p>…”

Primary endpoint analysis, i.e., time to first occurrence of combined event of 50% decrease in eGFR or ESRD. by Rozita Mohd (7411322)